Therapy News and Research

RSS

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

UNC Hospitals has received the American College of Cardiology Foundation's NCDR ACTION Registry-GWTG Silver Performance Achievement Award for 2010 - one of only 26 hospitals nationwide to do so.

26 Aug 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

Lockheed Martin awarded contracts to accelerate advancement of Nationwide Health Information Network

Lockheed Martin will take steps to accelerate the advancement of digital health records and secure health information exchanges with two new agreements to support the Nationwide Health Information Network. The contracts, which were awarded by the Department of Health and Human Services' Office of the National Coordinator for Health Information Technology (ONC), total $9 million over two years.

26 Aug 2010

Developing specific liver cell lines from stem cells holds promise for new liver disease treatment: Researchers

By creating diseased liver cells from a small sample of human skin, scientists have for the first time shown that stem cells can be used to model a diverse range of inherited disorders. The University of Cambridge researchers' findings, which will hopefully lead to new treatments for those suffering from liver diseases, were published today in The Journal of Clinical Investigation.

26 Aug 2010

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Atherotech Diagnostics Lab will exhibit its VAP Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update.

26 Aug 2010

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.

26 Aug 2010

Cornerstone Healthcare Plus REIT acquires $14.75M inpatient rehabilitation facility in Dallas

Cornerstone Real Estate Funds, and its strategic alliance partner and sub-advisor Servant Healthcare Investments, announced that the Cornerstone Healthcare Plus REIT has acquired an inpatient rehabilitation facility (IRF) for a purchase price of $14,750,000. The 42-bed, 40,000 square foot property is located in Dallas, Texas and is leased under a long-term lease to GlobalRehab LP.

26 Aug 2010

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma.

26 Aug 2010

Study finds autism patients have short-range over-connectivity in brain's cortex

There is still much that is unknown about autism spectrum disorders, but a University of Nevada, Reno psychologist has added to the body of knowledge that researchers around the world are compiling to try to demystify, prevent and treat the mysterious condition.

26 Aug 2010

IMA receives five-year renewal grant from National Science Foundation

The University of Minnesota's Institute for Mathematics and its Applications (IMA) has been awarded a $20.5-million National Science Foundation (NSF) renewal grant over the next five years. The renewal grant continues the IMA's tradition as one of the nation's top math institutes in terms of funding.

26 Aug 2010

Research finds adenovirus impact on cell's suicide program pave way for new cancer therapy

A novel mechanism used by adenovirus to sidestep the cell's suicide program, could go a long way to explain how tumor suppressor genes are silenced in tumor cells and pave the way for a new type of targeted cancer therapy, report researchers at the Salk Institute for Biological Studies in the Aug. 26, 2010 issue of Nature.

26 Aug 2010

Researchers prove iPS cells can help to treat liver diseases

Great excitement greeted the discovery a few years ago that certain cells from mice and humans could be reprogrammed to become inducible pluripotent stem cells (iPS cells), as they hold promise for cell replacement therapy and modeling human disease.

26 Aug 2010

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.

26 Aug 2010

Angeion Corporation 2010 third quarter revenue increases to $7.1 million

Angeion Corporation today reported results for its fiscal third quarter ended July 31, 2010.

26 Aug 2010

Opinions: Health and agriculture; GHI's main ideas; Recommendations to improve Haiti's government; China and the Global Fund

In a SciDev.Net opinion piece, Jeff Waage, director of the London International Development Centre, argues for more collaboration between agriculture and health experts. "The relationship between agriculture and health may seem intuitive and simple - grow more crops and people will have more food and live healthier lives.

26 Aug 2010

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Stem cell therapy cures 12-year-old boy with diabetes

Cellonis Biotechnologies, a Beijing and HK-based medical research and application company, has recorded some remarkable results in the treatment of a twelve-year-old boy with diabetes using their stem cell therapy in a Beijing partner hospital. He has completely regained his normal life, enjoying sports and school activities just like every other person his age, and has been free from injections and drugs for more than half a year.

25 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels.

25 Aug 2010

Therapy News and Research

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Lockheed Martin awarded contracts to accelerate advancement of Nationwide Health Information Network

Developing specific liver cell lines from stem cells holds promise for new liver disease treatment: Researchers

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Cornerstone Healthcare Plus REIT acquires $14.75M inpatient rehabilitation facility in Dallas

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Study finds autism patients have short-range over-connectivity in brain's cortex

IMA receives five-year renewal grant from National Science Foundation

Research finds adenovirus impact on cell's suicide program pave way for new cancer therapy

Researchers prove iPS cells can help to treat liver diseases

FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy

Angeion Corporation 2010 third quarter revenue increases to $7.1 million

Opinions: Health and agriculture; GHI's main ideas; Recommendations to improve Haiti's government; China and the Global Fund

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Stem cell therapy cures 12-year-old boy with diabetes

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News